Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapy for many malignant and nonmalignant hematological diseases. The curative effect of allo-HSCT results from both the chemotherapy/radiation in the conditioning regimen and the donor T-mediated graft-versus-host (GVH) response against the malignancy known as a graft-versus-leukemia (GVL) effect. In most cases, the GVH response is not limited against the malignant cells but is also mediated against host epithelial cells, causing graft-versus-host disease (GVHD).
No takes yet. Share an insight, caveat, or question.
MacDonald et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: